Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals has issued 10,000 new fully paid ordinary shares following the exercise or conversion of previously unquoted options or other unquoted convertible securities. The issuance, dated 23 March 2026 and formally notified to the market on 9 April 2026, slightly increases the company’s share capital base and reflects the ongoing transition of employee or incentive-related securities into listed equity, a routine step that can marginally enhance market liquidity and align stakeholders’ interests with long-term company performance.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX under the code TLX. The company focuses on developing and commercializing radiopharmaceutical and molecularly targeted therapies, primarily for the diagnosis and treatment of cancer and other serious diseases in global healthcare markets.
Average Trading Volume: 3,164,933
Technical Sentiment Signal: Hold
Current Market Cap: A$4.6B
Learn more about TLX stock on TipRanks’ Stock Analysis page.